Bristol-Myers beats forecasts, as newer drugs deliver

Thu Jan 24, 2013 7:32am EST

Jan 24 (Reuters) - Bristol-Myers Squibb Co reported better than expected quarterly sales and earnings, fueled by strong sales of newer treatments for leukemia, melanoma and diabetes.

The U.S. drugmaker on Thursday said it earned $925 million, or 56 cents per share, in the fourth quarter. That compared with $852 million, or 50 cents per share, in the year-earlier quarter.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.